Volume : 13, Issue : 03, March – 2026

Title:

A REVIEW ON ADVERSE EFFECTS, DRUG INTERACTIONS AND CONTRAINDICATIONS OF ORAL KETOCONAZOLE FORMULATION.

Authors :

Shubham R. Veer, Prof. Hemant J. Pagar

Abstract :

The imidazole topical ketoconazole has long been used to treat fungus diseases and seborrheic dermatitis. Ketoconazole inhibits fungus ergosterol production, a component of cell membranes, and has other antifungal properties. Ketoconazole is also available as a cream, solution, and shampoo to treat skin fungus diseases. common side effects include itching, nausea, rash, stomach pain, headache, vertigo, tiredness, impotence, menstruation irregularities, and gynecomastia. Ketoconazole foam and gel versions for the therapy of seborrheic dermatitis have recently been introduced to the market, and they are successful against superficial fungal and yeast diseases. In 1981, the FDA authorised ketoconazole as the first broad-spectrum dietary antifungal. Post-marketing complaints of hepatotoxicity, adrenocortical insufficiency, endocrine dysregulation, and medication interactions led in the medicine being withdrawn from the market in some countries and severe product relabelling in others.
Keywords: Oral Ketoconazole, Adverse effect of oral ketoconazole (hepatotoxicity, Adrenocortical Insufficiency, endocrine dysregulation), Contraindications of oral ketoconazole,

Cite This Article:

Please cite this article in press Shubham R. Veer et al., A Review On Adverse Effects, Drug Interactions And Contraindications Of Oral Ketoconazole Formulation ., Indo Am. J. P. Sci, 2026; 13(03).

REFERENCES:

1. Ketoconazole approved for systemic fungal infections. FDA Drug Bull. U.S. Food and Drug Administration 1981; 11:18-19
2. Cuce LC, Wroclawski EL, Sampaio SA. Treatment of Para coccidioidomycosis, candidiasis, chromomycosis, lobomycosis, and mycetoma with ketoconazole. Int J Dermatol 1980; 19:405-8
3. Varkey B. Oral antifungal therapy. Current status of ketoconazole. Postgrad Med 1983; 73:52-3
4. Sohn CA. Evaluation of ketoconazole. Clin Pharm 1982; 1:217-24
5. Thienpont D, Van Cutsem J, Van Gerven F, et al. Ketoconazole — a new broad spectrum orally active antimycotic. Experientia 1979; 35:606-7
6. Heel RC, Brogden RN, Carmine A, et al. Ketoconazole: a review of its therapeutic efficacy in superficial and systemic fungal infections. Drugs 1982; 23:1-36. Review of early clinical studies of efficacy and safety of oral ketoconazole in the treatment of systemic and superficial mycoses.
7. Lake-Bakaar G, Scheuer PJ, Sherlock S. Hepatic reactions associated with ketoconazole in the United Kingdom. Br Med J (Clin Res Ed) 1987; 294:419-22.
8. Stricker BH, Blok AP, Bronkhorst FB, et al. Ketoconazole-associated hepatic injury. A clinicopathological study of 55 cases. J Hepatol 1986; 3:399-406.
9. DeFelice R, Johnson DG, Galgiani JN. Gynecomastia with ketoconazole. Antimicrob Agents Chemother 1981; 19:1073-4.
10. Craven PC. Interaction of ketoconazole with rifampin and isoniazid. N Engl J Med 1985; 312:1061 12. D’Mello AP, D’Souza MJ, Bates TR. Pharmacokinetics of ketoconazole.
11. Murphy E, Hannon D, Callaghan B. Ketoconazole–theophylline interaction. Ir Med J 1987; 80:123-4.
12. European Medicines Agency. European Medicines Agency recommends suspension of marketing authorisations for oral ketoconazole [Internet] 2013.
13. Medicines and Healthcare products Regulatory Agency. Drug Safety Update: Oral ketoconazole: do not prescribe or use for fungal infections – risk of liver injury outweighs benefits [Internet] 2013.
14. European Medicines Agency. European Medicines Agency recommends suspension of marketing authorisations for oral ketoconazole. European Medicines Agency 2013;1-3.
15. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems. 2013
16. Health Canada. Health Canada Endorsed Important Safety Information on Ketoconazole [Internet]. Ketoconazole – Risk of Potentially Fatal Liver Toxicity – For Health Professionals.
17. Bodey GP. Azole antifungal agents. Clin Infect Dis 1992;14(Suppl 1): S161-9.
18. Van den Bossche H, Willemsens G, Cools W, et al. In vitro and in vivo effects of the antimycotic drug ketoconazole on sterol synthesis. Antimicrob Agents Chemother 1980; 17:922-8
19. Rodriguez RJ, Acosta D. Comparison of ketoconazole- and fluconazole-induced hepatotoxicity in a primary culture system of rat hepatocytes. Toxicology 1995; 96:83-92.
20. Rodriguez RJ, Acosta D. N-deacetyl ketoconazole-induced hepatotoxicity in a primary culture system of rat hepatocytes. Toxicology 1997; 117:123-31
21. Administration AGD of HTG. Oral ketoconazole (Nizoral) 200 mg tablets [Internet]. Available from: http://www. tga.gov.au/safety/alerts-medicine-oral-ketoconazole- 131010.htm
22. Bercoff E, Bernuau J, Degott C, et al. Ketoconazole-induced fulmi-nant hepatitis. Gut. 1985;26(6):636–638
23. Petersen EA, Alling DW, Kirkpatrick CH. Treatment of chronic mucocutaneous candidiasis with ketoconazole: a controlled clinical trial. Ann Intern Med 1980; 93:791-5
24. Westphal JF, Brogard JM. Antibacterial and antifungal agents. In: Kaplowitz N, DeLeve LD, editors. Drug induced liver disease. New York (NY): Marcel Dekker Publishing; 2003. p. 471–504.
25. García Rodríguez LA, Duque A, Castellsague J, et al. A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs. Br J Clin Pharmacol. 1999;48(6):847–852.
26. Chien RN, Yang LJ, Lin PY, et al. Hepatic injury during ketoconazole therapy in patients with onychomycosis: a controlled cohort study. Hepatology. 1997;25(1):103–107.
27. Sugar AM, Alsip SG, Galgiani JN, et al. Pharmacology and toxicity of high-dose ketoconazole. Antimicrob Agents Chemother 1987; 31:1874-8
28. Stevens DA, Stiller RL, Williams PL, Sugar AM. Experience with ketoconazole in three major manifestations of progressive coccidioidomycosis. Am J Med 1983; 74:58-63
29. Santen RJ, Van den Bossche H, Symoens J, et al. Site of action of low dose ketoconazole on androgen biosynthesis in men. J Clin Endocrinol Metab 1983; 57:732-6
30. Pont A, Williams PL, Azhar S, et al. Ketoconazole blocks testosterone synthesis. Arch Intern Med 1982; 142:2137-40
31. Pont A, Graybill JR, Craven PC, et al. High-dose ketoconazole therapy and adrenal and testicular function in humans. Arch Intern Med 1984; 144:2150-3
32. Pont A, Goldman ES, Sugar AM, et al. Ketoconazole-induced increase in estradiol- testosterone ratio. Probable explanation for gynecomastia. Arch Intern Med 1985; 145:1429-31
33. Loose DS, Kan PB, Hirst MA, et.al: ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes. J clin Invest 71:1495-1499,1983
34. Engelhardt D, Mann K, H6rmann R, Braun S, Karl HJ (1983) Ketoconazole inhibits cortisol secretion of an adrenal adenoma in vivo and in vitro. Klin Wochenschr 61: 373- 375
35. D S Loose, R A Marcus, D Feldman, “Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes”, “The Journal of clinical Investigation”, J Clin Invest. 1983;71(5):1495-1499
36. Gascoigne EW, Barton GJ, Michaels M, Meuldermans W, Hey-kants J. The kinetics of ketoconazole in animals and man. Clinical Research Reviews I: 177-187, 1981
37. Brass C, Galgiani IN, Blaschke TF, Defelice R, O’Reilly RA, et al. Disposition of ketoconazole, an oral antifungal, in humans. Antimicrobial Agents and Chemotherapy 27: 151-158, 1982
38. Mannisto PT, Mantyla R, Nykanen S, Lamminsivu U, Ottoila P. Impairing effect of food on ketoconazole absorption. Anti-microbial agents and Chemotherapy 21: 730-133, 1982
39. Daneshmend TK, Warnock DW, Ene MD, Johnson EM, Potten MR, et al. Influence of food on the pharmacokinetics of ketoconazole. Antimicrobial Agents and Chemotherapy 25: 1-3, 1984
40. Fazio RA, Wickremesinghe PC, Arsura EL. Ketoconazole treatment of Candida esophagitis: a prospective study of 12 cases. American Journal of Gastroenterology 78: 261-264, 1983
41. Magnasco AJ, Magnasco LD. Interaction of ketoconazole and ethanol. Clinical Pharmacy 5: 522-523, 1986
42. Smith EB, Henry Je. Ketoconazole: an orally effective antifungal agent. Pharmacotherapy 4: 199-204, 1984
43. Brown MW, Maldonado AL, Meredith CG, Speeg KV. Effect of ketoconazole on hepatic oxidative drug metabolism. Clinical Pharmacology and Therapeutics 37: 290-297, 1985
44. Cunningham C, Burke MD, Whiting PH, Simpson JG, Wheatley ON. Ketoconazole, cyclosporin and the kidney. Lancet 2: 1464. 1982
45. Smith JM, Hows JM, Gordon-Smith EC, Baughan A, Goldman JM. Interaction of cyclosporin A and ketoconazole. Clinical Science 64: 67P-68P, 1983
46. Cunningham C, Whiting PH, Burke MD, Wheatley DN, Simpson JG. Increasing the hepatic metabolism of cyclosporin abolishes nephrotoxicity. Transplantation Proceedings 15 (Suppl. I): 2712- 2715, 1983
47. Gumbleton M, Brown JE, Hawksworth G, Whiting PH. The possible relationship between hepatic drug metabolism and ketoconazole enhancement of cyclosporine nephrotoxicity. Transplantation 40: 454-455, 1985
48. Meunier-Carpentier F, Heymans C, Snoeck R. Interaction of rifampicin with ketoconazole and Bay n7133 in normal volunteers. Presented at the 23rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Las Vegas, October 24- 26, 1983
49. Glynn AM, Slaughter RL, Brass C, D’Ambrosio R, Jusko WJ. Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion. Clinical Pharmacology and Therapeutics 39: 654-659, 198
50. KD Tripathi “Essential of Medical Pharmacology”, “Jaypee Brothers Medical Publishers
(P) Ltd”, 8th Edition, 2019 Pg.no.844
51. KD Tripathi, “Essential of Medical Pharmacology”, “Jaypee Brothers Medical Publishers
(P) Ltd”, 6th Edition, 2008, Chapter 57, Pg.no.763
52. James M. Ritter, “Rang and Dale’s Pharmacology”, “Elsevier Health Sciences”, 8th Edition, 2020, Chapter 54, Pg.no.693